Bouchey Financial Group’s Pacira BioSciences PCRX Stock Holding History
Bought
Maintained
Sold
Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
---|---|---|---|---|---|---|---|---|
2023
Q3 | – | Sell |
-5,500
| Closed | -$220K | – | 131 |
|
2023
Q2 | $220K | Hold |
5,500
| – | – | 0.03% | 103 |
|
2023
Q1 | $224K | Hold |
5,500
| – | – | 0.03% | 94 |
|
2022
Q4 | $212K | Hold |
5,500
| – | – | 0.03% | 86 |
|
2022
Q3 | $293K | Hold |
5,500
| – | – | 0.04% | 73 |
|
2022
Q2 | $321K | Hold |
5,500
| – | – | 0.05% | 68 |
|
2022
Q1 | $420K | Hold |
5,500
| – | – | 0.06% | 63 |
|
2021
Q4 | $331K | Hold |
5,500
| – | – | 0.04% | 75 |
|
2021
Q3 | $308K | Hold |
5,500
| – | – | 0.04% | 72 |
|
2021
Q2 | $334K | Hold |
5,500
| – | – | 0.05% | 57 |
|
2021
Q1 | $385K | Buy |
5,500
+1,000
| +22% | +$70K | 0.06% | 55 |
|
2020
Q4 | $269K | Hold |
4,500
| – | – | 0.05% | 65 |
|
2020
Q3 | $271K | Hold |
4,500
| – | – | 0.05% | 55 |
|
2020
Q2 | $236K | Buy |
+4,500
| New | +$236K | 0.05% | 58 |
|
2020
Q1 | – | Sell |
-4,500
| Closed | -$204K | – | 69 |
|
2019
Q4 | $204K | Buy |
+4,500
| New | +$204K | 0.05% | 78 |
|
2018
Q4 | – | Sell |
-4,500
| Closed | -$221K | – | 77 |
|
2018
Q3 | $221K | Buy |
+4,500
| New | +$221K | 0.05% | 68 |
|
2018
Q1 | – | Sell |
-4,500
| Closed | -$205K | – | 69 |
|
2017
Q4 | $205K | Buy |
+4,500
| New | +$205K | 0.06% | 66 |
|
2016
Q2 | – | Sell |
-4,550
| Closed | -$241K | – | 66 |
|
2016
Q1 | $241K | Hold |
4,550
| – | – | 0.1% | 53 |
|
2015
Q4 | $349K | Buy |
+4,550
| New | +$349K | 0.15% | 45 |
|
2015
Q3 | – | Sell |
-4,500
| Closed | -$318K | – | 64 |
|
2015
Q2 | $318K | Sell |
4,500
-1,700
| -27% | -$120K | 0.14% | 48 |
|
2015
Q1 | $551K | Sell |
6,200
-300
| -5% | -$26.7K | 0.25% | 41 |
|
2014
Q4 | $576K | Buy |
6,500
+2,000
| +44% | +$177K | 0.27% | 41 |
|
2014
Q3 | $436K | Sell |
4,500
-1,500
| -25% | -$145K | 0.22% | 46 |
|
2014
Q2 | $551K | Hold |
6,000
| – | – | 0.3% | 44 |
|
2014
Q1 | $420K | Hold |
6,000
| – | – | 0.26% | 47 |
|
2013
Q4 | $390K | Buy |
+6,000
| New | +$390K | 0.27% | 46 |
|